D-EYE

D-EYE provides portable eye and retinal imaging system.

Founded in 2015 as a spin off by Italian Incubator M31 Italia Srl and technology developer Si14, Spa of Padova Italy, the company has developed the first modern day smartphone based digital ophthalmascope bringing back a rebirth to clinical practice, the important 140 year old ophthalmoscopy examination. The company’s first product, the D-EYE Retinal Screening System enables clinicians and organizations to perform mass health screenings and data collection to improve vital health examination services. Known as the “digital eye” into the state of the human body, the smartphone based D-EYE lens and on-board application allows anyone with minimal training to screen patients eyes for various health issues including Glaucoma, Diabetic Retinopathy and Macular Degeneration; three serious pathologies causing blindness of millions of people annually. The on-board D-EYE application creates a detailed patient record that can be shared instantly with other clinicians anywhere there is a cellular or internet connection. Today, D-EYE is being used by Ophthalmologists, Emergency Physicians, Neurologists, Pediatricians, to name a few vertical specialists that perform ophthalmoscopies everyday. Combined with Apple TV, medical schools and other teaching institutions are using D-EYE to teach students and rotating Residents about the retina through both shared and self examination. With the basic on-board D-EYE application development completed , new investment will be used to develop needed Hipaa compliant institutional integration processes and service based revenue product development initiatives that include: • Development required gold standard field of view stitching algorithm, a breakthrough smartphone and cloud based system (Single fee based revenue service via the web) • Develop and utilizing existing machine learned artificial intelligence algorithms for initial assessment in the field (Revenue based on millions of exams) • Global revenue based digital telehealth services insuring specific pathologies are monitored reducing growing high incidence of blindness from catastrophic disease (Revenue based reader service provided by contract based Board Certified Ophthalmology MD’s) • Integration exam and reader services with global EHR systems providing (revenue based auto integration from 3rd party clinicians) • Data aggregation and mining processes to track various diseases on a global basis (Revenue based use of data subscription) With offices in Padova Italy and Truckee California, D-EYE has developed relationships with hundreds of clinicians and dozens of institutions in the US and the EU who are leading the protocol development to best utilize the D-EYE Retinal System to close the gap between serious eye disease and missed patient diagnosis causing preventable blindness for millions of patients who do not have easy and prescribed scheduled access to eye examinations on a regular basis. D-EYE sells both directly to clinicians and institutions and has developed global distribution relationships in countries around the word including many EU countries, UK, Canada, Middle East, Japan, South Africa with medical device registration in process in China, Brazil, Chile and Argentina. D-EYE received FDA clearance and CE mark in late 2015, and recently completed 2nd year ISO 13485, 13485 Canada and 9001 audits in June and July 2017.